A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly

被引:20
|
作者
Wang, Peng [1 ]
Zhang, Dong [1 ]
Guo, Xue-Guang [1 ]
Li, Xiao-Mei [1 ]
Du, Le-Hui [2 ]
Sun, Bao-Jun [3 ]
Fang, Xiang-Qun [3 ]
Guo, Ying-Hua [3 ]
Guo, Jun [3 ]
An, Li [3 ]
Qu, Ge-Ping [3 ]
Liu, Chang-Ting [3 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Nanlou Med Oncol Dept, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Radiat Oncol, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Nanlou Resp Dis Dept, 28 Fu Xing Rd, Beijing 100853, Peoples R China
关键词
geriatric; non-small cell lung cancer; stereotactic body radiotherapy; surgery; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; SUBLOBAR RESECTION; SURGICAL RESECTION; OUTCOMES; LOBECTOMY; SURVIVAL; STATISTICS; RECURRENCE; STRATEGIES;
D O I
10.1097/MD.0000000000005723
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Elderly patients with early stage non-small cell lung cancer (NSCLC) who undergo surgical resection are at a high risk of treatment-related complications. Stereotactic body radiation therapy (SBRT) is considered an alternative treatment option with a favorable safety profile. Given that prospective comparative data on SBRT and surgical treatments are limited, we compared the 2 treatments for early stage NSCLC in the elderly. We retrospectively collected information from the database at our geriatric institution on patients with clinical stage IA/B NSCLC who were treated with surgery or SBRT. The patients were matched using a propensity score based on gender, age, T stage, tumor location, pulmonary function (forced expiratory volume in 1 second [FEV1]% and FEV1), Charlson comorbidity score, and World Health Organization performance score. We compared locoregional control rate, recurrence-free survival (RFS), overall survival (OS), and cancer-specific survival (CSS) between the 2 treatment cohorts before and after propensity score matching. A total of 106 patients underwent surgery, and 74 received SBRT. Surgical patients were significantly younger (72.6 +/- 7.9 vs 82.6 +/- 4.1 years, P=0.000), with a significantly higher rate of adenocarcinoma (P=0.000), better Eastern Cooperative Oncology Group performance scores (P=0.039), and better pulmonary function test results (P=0.034 for predicted FEV1 and P=0.032 for FEV1). In an unmatched comparison, there were significant differences in locoregional control (P=0.0012) and RFS (P<0.001). The 5-year OS was 69% in patients who underwent surgery and 44.6% in patients who underwent SBRT (P=0.0007). The 5-year CSS was 73.9% in the surgery group and 57.5% in the SBRT group (P=0.0029). Thirty-five inoperable or marginally operable surgical patients and 35 patients who underwent SBRT were matched to their outcomes in a blinded manner (1: 1 ratio, caliper distance=0.25). In this matched comparison, the follow-up period of this subgroup ranged from 4.2 to 138.1 months, with a median of 58.7 months. Surgery was associated with significantly better locoregional control (P=0.0191) and RFS (P=0.0178), whereas no significant differences were found in OS (5-year OS, 67.8% for surgery vs 47.4% for SBRT, P=0.07) or CSS (67.8% for surgery vs 58.2% for SBRT, P=0.1816). This retrospective analysis found superior locoregional control rates and RFS after surgery compared with SBRT, but there were no differences in OS or CSS. SBRT is an alternative treatment option to surgery in elderly NSCLC patients who cannot tolerate surgical resection because of medical comorbidities. Our findings support the need to compare the 2 treatments in randomized controlled trials.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Substantial imbalance that is never eliminated with propensity score matched analyses in comparing surgery to stereotactic body radiotherapy for patients with early-stage non-small cell lung cancer
    Takeda, Atsuya
    Tsurugai, Yuichiro
    Sanuki, Naoko
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S1415 - S1419
  • [22] Stereotactic body radiotherapy for stage I non-small cell lung cancer
    Martel-Lafay, I.
    ONCOLOGIE, 2012, 14 (05) : 282 - 288
  • [23] Stereotactic body radiotherapy for stage I non-small cell lung cancer
    Slotman, Ben J.
    JOURNAL OF RADIOSURGERY AND SBRT, 2011, 1 (01): : 63 - 69
  • [24] Quality of Life after Stereotactic Body Radiotherapy and Surgery in Patients with Early Stage Non-Small Cell Lung Cancer
    Kastelijn, Elisabeth
    El Sharouni, Sherif
    Hofman, Frederik
    Zanen, Pieter
    Schramel, Franz
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S633 - S634
  • [25] Surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer: review of meta-analyses
    Hamaji, Masatsugu
    Matsuo, Yukinori
    Chen-Yoshikawa, Toyofumi Fengshi
    Mizowaki, Takashi
    Date, Hiroshi
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S1646 - S1652
  • [26] Comparative Effectiveness of Lobectomy, Sublobar Resection, and Stereotactic Body Radiation Therapy for Clinical Stage I Non-Small Cell Lung Cancer: A Propensity-Matched Analysis
    Shaikh, T.
    Churilla, T. M.
    Murphy, C. T.
    Hallman, M. A.
    Scott, W. J.
    Meyer, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E451 - E452
  • [27] Stereotactic Body Radiation Therapy and Surgery for Early Stage Non-Small Cell Lung Cancer
    Piperis, Maria
    Tsoukalas, Nikolaos
    JOURNAL OF INVESTIGATIVE SURGERY, 2018, 31 (05) : 448 - 449
  • [28] STEREOTACTIC ABLATIVE RADIOTHERAPY OF EARLY STAGE NON-SMALL CELL LUNG CANCER
    Cvek, Jakub
    Feltl, David
    Knybel, Lukas
    Otahal, Bretislav
    Skacelikova, Eva
    Binarova, Andrea
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S537 - S537
  • [29] Significance of stereotactic body radiotherapy in older patients with early stage non-small cell lung cancer
    Maebayashi, Toshiya
    Ishibashi, Naoya
    Aizawa, Takuya
    Sakaguchi, Masakuni
    Saito, Tsutomu
    Kawamori, Jiro
    Tanaka, Yoshiaki
    JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (06) : 594 - 599
  • [30] Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
    Hu, Chen
    JAMA ONCOLOGY, 2024, 10 (11) : 1576 - 1577